Zhao Jing-Yi, Ma Xue-Lei, Li Yan-Yan, Zhang Bing-Lan, Li Min-Min, Ma Xue-Lei, Liu Lei
Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China E-mail :
Asian Pac J Cancer Prev. 2014;15(8):3525-31. doi: 10.7314/apjcp.2014.15.8.3525.
Fluorine-18-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) is a new technique for identifying different malignant tumors using different uptake values between tumor cells and normal tissues. Here we assessed the diagnostic accuracy of 18F-FDG-PET in patients with testicular cancer by pooling data of existing trials in a meta-analysis.
PubMed/MEDLINE, Embase and Cochrane Central Trials databases were searched and studies published in English relating to the diagnostic value of FDG-PET for testicular cancer were collected. The summary receiver operating characteristic (SROC) curve was used to examine the FDG-PET accuracy.
A total of 16 studies which included 957 examinations in 807 patients (median age, 31.1 years) were analyzed. A meta-analysis was performed to combine the sensitivity and specificity and their 95% confidence intervals (CIs), from diagnostic odds ratio (DOR), positive likelihood ratios (PLR), negative likelihood ratio (NLR). SROC were derived to demonstrate the diagnostic accuracy of FDG-PET for testicular cancer. The pooled sensitivity and specificity were 0.75 (95% confidence interval (CI), 0.70-0.80) and 0.87 (95% CI, 0.84-0.89), respectively. The pooled DOR was 35.6 (95% CI, 12.9-98.3). The area under the curve (AUC) was 0.88. The pooled PLR and pooled NLR were 7.80 (95% CI, 3.73-16.3) and 0.31 (95% CI, 0.23-0.43), respectively.
In patients with testicular cancer, 18F-FDG-PET demonstrated a high SROC area, and could be a potentially useful tool if combined with other imaging methods such as MRI and CT. Nevertheless, the literature focusing on the use of 18F-FDG-PET in this setting still remains limited.
氟-18-氟脱氧葡萄糖正电子发射断层扫描（18F-FDG-PET）是一种利用肿瘤细胞与正常组织之间不同摄取值来识别不同恶性肿瘤的新技术。在此，我们通过荟萃分析汇总现有试验数据，评估18F-FDG-PET对睾丸癌患者的诊断准确性。
检索PubMed/MEDLINE、Embase和Cochrane Central Trials数据库，收集以英文发表的有关FDG-PET对睾丸癌诊断价值的研究。采用汇总受试者工作特征（SROC）曲线来检验FDG-PET的准确性。
共分析了16项研究，包括对807例患者（中位年龄31.1岁）进行的957次检查。进行荟萃分析以合并敏感性和特异性及其95%置信区间（CI），计算诊断比值比（DOR）、阳性似然比（PLR）、阴性似然比（NLR）。推导SROC曲线以证明FDG-PET对睾丸癌的诊断准确性。汇总敏感性和特异性分别为0.75（95%置信区间（CI），0.70 - 0.80）和0.87（95% CI，0.84 - 0.89）。汇总DOR为35.6（95% CI，12.9 - 98.3）。曲线下面积（AUC）为0.88。汇总PLR和汇总NLR分别为7.80（95% CI，3.73 - 16.3）和0.31（95% CI，0.23 - 0.43）。
在睾丸癌患者中，18F-FDG-PET显示出较高的SROC面积，如果与MRI和CT等其他成像方法联合使用，可能是一种有用的工具。然而，专注于18F-FDG-PET在这种情况下应用的文献仍然有限。
